Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736165PMC
http://dx.doi.org/10.1016/j.gimo.2024.101875DOI Listing

Publication Analysis

Top Keywords

casgevy exagamglogene
4
exagamglogene autotemcel
4
autotemcel lyfgenia
4
lyfgenia lovotibeglogene
4
lovotibeglogene autotemcel
4
autotemcel individuals
4
individuals years
4
years older
4
older sickle
4
sickle cell
4

Similar Publications

Article Synopsis
  • - Sickle cell disease (SCD) is a hereditary blood disorder that leads to chronic pain, anemia, and various health complications, but advancements in treatments have improved patient outcomes over time.
  • - Despite progress, challenges like limited access to stem cell transplants and complications from current therapies highlight the need for ongoing research in SCD treatments.
  • - The recent FDA approval of Casgevy, a CRISPR/Cas9-based gene therapy, represents a significant step in SCD treatment, with the review focusing on its potential effectiveness and safety compared to traditional methods, emphasizing the need for long-term research.
View Article and Find Full Text PDF

Sickle cell disease (SCD), the most common autosomal recessive genetic disorder, affects the hemoglobin (Hb) chains in human red blood cells. It is caused by mutations in the β-globin genes, leading to the production of hemoglobin S, which results in the formation of sickle-shaped red blood cells (RBCs). These abnormal cells cause hemolysis, endothelial damage, and small vessel occlusion, leading to both acute and long-term complications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!